Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras

被引:27
作者
Brassard, DL
English, JM
Malkowski, M
Kirschmeier, P
Nagabhushan, TL
Bishop, WR
机构
[1] Schering Plough Res Inst, Biotechnol Dev, Union, NJ 07083 USA
[2] Schering Plough Corp, Res Inst, Biol Res Oncol, Kenilworth, NJ 07033 USA
[3] DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA
关键词
D O I
10.1006/excr.2001.5440
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Farnesyl protein transferase inhibitors (FTIs) reverse the transformed phenotype of fibroblasts expressing activated H-Ras and block anchorage-independent growth and tumorigenesis of tumor cell lines independent of their Ras mutational status. FTIs induce significant tumor regression accompanied by apoptosis in several transgenic mouse tumor models. FTI treatment of tumor cells in vitro is proapoptotic under certain cell culture conditions. Induction of apoptosis by FTIs in vitro generally requires a second death-promoting signal. To better understand FTI-induced apoptosis we analyzed the effect of SCH 66336, a tricyclic FTI, on apoptosis of Ras-transformed Rat2 fibroblasts. Treatment of H-Ras-CVLS-transformed fibroblasts with MEK1,2 inhibitors provides a pharmacological second signal to enhance FTI-induced apoptosis. Simultaneous treatment of these cells with a MEK1,2 inhibitor markedly enhanced caspase-3 activity and the apoptotic response to SCH 66336. The combination treatment resulted in a more complete and sustained inhibition of MAPK pathway activity than observed with either drug alone. Surprisingly, after treatment with either agent alone or in combination, no apoptotic response was observed in Rat2 cells transformed with a geranylgeranylated form of H-Ras (H-Ras-CVLL). Differences were also observed when SCH 66336 treatment was combined with forced suspension growth or serum withdrawal, in that an increase in drug-induced apoptosis was observed in H-Ras-CVLS-transformed Rat2 cells but not H-Ras-CVLL-transformed Rat2 cells. The: lack of apoptotic effect of SCH 66336 and MEK inhibitor, alone or in combination, in H-Ras-CVLL-transformed cells suggests a difference in the reliance of cells transformed with farnesylated and geranylgeranylated forms of H-Ras on the MAPK signal transduction cascade for survival. K-Ras-transformed cells underwent apoptosis upon MEK1,2 inhibition but not in response to SCH 66336 treatment. The apoptotic response induced by MEK1,2 inhibitors is much greater in magnitude in H-Ras-transformed cells than in K-Ras-transformed cells, also pointing to differences in pathway utilization and/or dependence for these two Ras isoforms. (C) 2002 Elsevier Science (USA).
引用
收藏
页码:138 / 146
页数:9
相关论文
共 38 条
[1]   Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules [J].
Ashar, HR ;
James, L ;
Gray, K ;
Carr, D ;
Black, S ;
Armstrong, L ;
Bishop, WR ;
Kirschmeier, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (39) :30451-30457
[2]   A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis [J].
Barrington, RE ;
Subler, MA ;
Rands, E ;
Omer, CA ;
Miller, PJ ;
Hundley, JE ;
Koester, SK ;
Troyer, DA ;
Bearss, DJ ;
Conner, MW ;
Gibbs, JB ;
Hamilton, K ;
Koblan, KS ;
Mosser, SD ;
O'Neill, TJ ;
Schaber, MD ;
Senderak, ET ;
Windle, JJ ;
Oliff, A ;
Kohl, NE .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (01) :85-92
[3]   Novel tricyclic inhibitors of farnesyl protein transferase - Biochemical characterization and inhibition of Ras modification in transfected Cos cells [J].
Bishop, WR ;
Bond, R ;
Petrin, J ;
Wang, L ;
Patton, R ;
Doll, R ;
Njoroge, G ;
Catino, J ;
Schwartz, J ;
Windsor, W ;
Syto, R ;
Schwartz, J ;
Carr, D ;
James, L ;
Kirschmeier, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (51) :30611-30618
[4]   Integrin αvβ3-mediated activation of apoptosis [J].
Brassard, DL ;
Maxwell, E ;
Malkowski, M ;
Nagabhushan, TL ;
Kumar, CC ;
Armstrong, L .
EXPERIMENTAL CELL RESEARCH, 1999, 251 (01) :33-45
[5]   Increasing complexity of Ras signaling [J].
Campbell, SL ;
Khosravi-Far, R ;
Rossman, KL ;
Clark, GJ ;
Der, CJ .
ONCOGENE, 1998, 17 (11) :1395-1413
[6]   The C-terminal polylysine region and methylation of K-Ras are critical for the interaction between K-Ras and microtubules [J].
Chen, Z ;
Otto, JC ;
Bergo, MO ;
Young, SG ;
Casey, PJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (52) :41251-41257
[8]   SPECIFIC ISOPRENOID MODIFICATION IS REQUIRED FOR FUNCTION OF NORMAL, BUT NOT ONCOGENIC, RAS PROTEIN [J].
COX, AD ;
HISAKA, MM ;
BUSS, JE ;
DER, CJ .
MOLECULAR AND CELLULAR BIOLOGY, 1992, 12 (06) :2606-2615
[9]   DEVELOPMENT OF A PROPIDIUM IODIDE FLUORESCENCE ASSAY FOR PROLIFERATION AND CYTOTOXICITY ASSAYS [J].
DENGLER, WA ;
SCHULTE, J ;
BERGER, DP ;
MERTELSMANN, R ;
FIEBIG, HH .
ANTI-CANCER DRUGS, 1995, 6 (04) :522-532
[10]  
Du W, 1999, CANCER RES, V59, P4208